Theranexus Announces Positive Data on Efficacy and Safety in the Phase I/II Trial of Batten-1
Theranexus Announces Positive Data on Efficacy and Safety in the Phase I/II Trial of Batten-1 Stabilizat...
Wall Street Journal Article by Judy Stecker
Pediatric rare disease drug development relies on the commitment, motivation, and tenacity of the parents...
Amicus Discontinuing Their CLN6 program
Like many in our Batten community, we are disappointed to hear that Amicus have chosen to discontinue the...
BBDF Supporting the National Institutes of Health CLN3 Natural History Study
BBDF is proud to support the CLN3 Natural History Study at the National Institutes of Health (NIH). A sum...
National Institutes of Health Seek Individuals to Participate in a Research Study
Researchers at the National Institutes of Health (NIH), in Bethesda, Maryland, seek individuals with CLN3...
Highly Promising 12-month results in the Phase I/II trial of Batten-1
Lyon, France – Austin, Texas, United States – 29 September 2023 – 7.30am – CET – Theranexus, a biopharmac...
Rare Sibling Stories Looking for Stories!
Rare Sibling Stories is looking for siblings to highlight on their platforms! They would love to feature...
NORD’s Batten Disease Patient Assistance Program
Having a rare disease is difficult. Adding in the complex care required to treat or manage that disease a...
BBDF Grants $60,000 Over 3-Years to Support Ineka Whiteman, Ph.D., Head of Research and Medical Affairs
BBDF grants $60,000 over 3-years to the BDSRA Foundation to support Ineka Whiteman, Ph.D. to serve as the...
Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)
Lyon, France – Austin, Texas, United States – 14 June 2023 – 7.30am CEST – Theranexus, a biopharmaceutica...